Endocrine News and Research

RSS

Pregnancy triggers profound brain changes, enhancing maternal instincts and mental health

A groundbreaking study reveals that pregnancy leads to a U-shaped pattern in gray matter volume, driven by hormonal changes and linked to maternal attachment.

19 Jan 2025

New rabbit model provides insights into CF-related pancreatic endocrine pathology

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction representing a critical and often overlooked complication.

17 Jan 2025

PFAS in US water linked to increased cancer risk

A study links PFAS contamination in drinking water to increased cancer risks, highlighting significant impacts on digestive, endocrine, and respiratory systems.

16 Jan 2025

Unveiling the genetic roots of bicuspid aortic valve

Large and rare duplications and deletions in a chromosome region known as 22q11.2 , which involves genes that regulate cardiac development, are linked to nonsyndromic bicuspid aortic valve disease, according to a new study led by UTHealth Houston researchers.

16 Jan 2025

Semaglutide improves glycemic control with automated insulin delivery

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin requirements and aiding weight management.

15 Jan 2025

Study unravels the links between obesity and cancer

Obesity, recognized as a complex and growing health issue, is associated with an increased risk of various cancers. A comprehensive review provides insights into the mechanisms linking obesity to cancer risk and discusses potential clinical implications.

15 Jan 2025

New push for stricter chemical laws to shield kids from harmful exposure

Research highlights the rising impact of synthetic chemicals on children's health, linking them to noncommunicable diseases and advocating for stringent global regulations.

13 Jan 2025

Menarini Group signs licensing deal with Insilico for promising cancer treatment

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.

10 Jan 2025

Puberty blockers and gender-affirming hormones rarely prescribed to transgender youth

Puberty blockers and gender-affirming hormones are rarely prescribed to U.S. transgender and gender diverse (TGD) adolescents, according to a new study from researchers at Harvard T.H. Chan School of Public Health, Harvard Pilgrim Health Care Institute, and FOLX Health.

6 Jan 2025

Research explores how carbon nanotubes help remove steroid hormones from water

Steroid hormones are among the most widespread aquatic micropollutants. They are harmful to human health, and they cause ecological imbalances in aquatic environments.

2 Jan 2025

Nonpharmacologic pain intervention provides benefits to people with dialysis-dependent kidney failure

Among people with dialysis-dependent kidney failure, a form of psychological therapy called pain coping skills training reduced how much pain got in the way of their daily lives, also known as pain interference.

30 Dec 2024

European Society of Endocrinology announces first-ever World Hormone Day in 2025

After three successful years of raising awareness of the importance of good hormone health through European Hormone Day, the European Society of Endocrinology (ESE) and the European Hormone and Metabolism Foundation (ESE Foundation), have announced the first-ever World Hormone Day to take place on 24 April 2025.

24 Dec 2024

Study reveals tumor and immune cell interactions in craniopharyngiomas

Craniopharyngiomas are brain tumors that negatively impact the hormonal function of the nearby pituitary.

16 Dec 2024

ZEST trial fails to meet enrollment goals for ctDNA testing in breast cancer

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients positive for ctDNA, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer would have better outcomes from adding CDK4/6 inhibitors to endocrine therapy as first-line treatment, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Active monitoring for low-risk DCIS results in similar quality of life as standard treatment

Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

COMET trial shows active monitoring is noninferior to standard treatment for low-risk DCIS

Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ipsilateral breast cancer recurrence rates as those who underwent guideline-concordant treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).

12 Dec 2024

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer - as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients, regardless of ESR1 mutation status - according to results from the phase III EMBER-3 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Endocrine News and Research

Pregnancy triggers profound brain changes, enhancing maternal instincts and mental health

New rabbit model provides insights into CF-related pancreatic endocrine pathology

PFAS in US water linked to increased cancer risk

Unveiling the genetic roots of bicuspid aortic valve

Semaglutide improves glycemic control with automated insulin delivery

Study unravels the links between obesity and cancer

New push for stricter chemical laws to shield kids from harmful exposure

Menarini Group signs licensing deal with Insilico for promising cancer treatment

Puberty blockers and gender-affirming hormones rarely prescribed to transgender youth

Research explores how carbon nanotubes help remove steroid hormones from water

Nonpharmacologic pain intervention provides benefits to people with dialysis-dependent kidney failure

European Society of Endocrinology announces first-ever World Hormone Day in 2025

Study reveals tumor and immune cell interactions in craniopharyngiomas

ZEST trial fails to meet enrollment goals for ctDNA testing in breast cancer

Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer

Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients

Active monitoring for low-risk DCIS results in similar quality of life as standard treatment

COMET trial shows active monitoring is noninferior to standard treatment for low-risk DCIS

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News